Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

April 29, 2021 Auto Bot Clinical Trials 0

Shots:

  • The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg, IV) vs PBO over 4days in patients with CSA-AKI across the US, Canada, Brazil, and Georgia
  • The first dose was given within 4hrs. of the completion of surgery with subsequent doses @24hrs. interval. The 1EP is an increased percentage of serum creatinine above baseline, starting from 24hrs. after the end of cardiopulmonary bypass surgery through day 6.
  • The companies plan to initiate confirmatory trial early in 2022, following the results of P-II study as well as discussions with the FDA and other relevant health authorities. The topline data is expected in H2’21

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Linkedin

The post Angion and Vifor Pharma Report Completion of Patient Enrollment in P-II AKI-002-15 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury first appeared on PharmaShots.